Radioactive drug shows promise in slowing advanced gut tumors
NCT ID NCT05459844
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This phase 3 study tested a radioactive drug called Lutetium-177 oxodotreotide against a high-dose standard drug (Octreotide LAR) in 196 adults with advanced neuroendocrine tumors that could not be removed by surgery. The goal was to see which treatment better delayed tumor growth. Participants received either the radioactive injection or the standard hormone therapy, and the study measured how long they lived without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, 646000, China
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
-
Henan Provincial People's Hospital
Zhengzhou, Henan, 450003, China
-
Mianyang Central Hospital
Mianyang, Sichuan, 621099, China
-
Nanjing First Hospital
Nanjing, Jiangsu, 210006, China
-
Qilu Hospital of Shandong University
Jinan, Shandong, 250012, China
-
The First Affiliated Hospital of AFMU
Xi'an, Shaanxi, 710032, China
-
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, 510630, China
-
The First Affiliated Hospital of Shanxi Medical University
Taiyuan, Shanxi, 030012, China
-
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510080, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, 361003, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
The First Afilliated Hospital of Fujian Medical University
Fuzhou, Fujian, 350005, China
-
The first hospital of Jilin University
Changchun, Jilin, 130021, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, 430030, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.